A detailed history of Vanguard Group Inc transactions in X Biotech Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,061,979 shares of XBIT stock, worth $7.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,061,979
Previous 1,036,969 2.41%
Holding current value
$7.03 Million
Previous $5.33 Million 54.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.55 - $7.95 $138,805 - $198,829
25,010 Added 2.41%
1,061,979 $8.21 Million
Q2 2024

Aug 13, 2024

BUY
$4.54 - $9.89 $643,109 - $1.4 Million
141,654 Added 15.82%
1,036,969 $5.33 Million
Q1 2024

May 10, 2024

BUY
$4.03 - $8.13 $55,630 - $112,226
13,804 Added 1.57%
895,315 $7.28 Million
Q4 2023

Feb 14, 2024

BUY
$3.56 - $4.65 $32,282 - $42,166
9,068 Added 1.04%
881,511 $3.53 Million
Q2 2023

Aug 14, 2023

BUY
$3.06 - $6.38 $55,000 - $114,674
17,974 Added 2.1%
872,443 $5.18 Million
Q4 2022

Feb 10, 2023

BUY
$3.03 - $3.79 $1,066 - $1,334
352 Added 0.04%
854,469 $3 Million
Q3 2022

Nov 14, 2022

SELL
$3.58 - $5.88 $630 - $1,034
-176 Reduced 0.02%
854,117 $3.09 Million
Q2 2022

Aug 12, 2022

SELL
$5.13 - $9.2 $381,589 - $684,332
-74,384 Reduced 8.01%
854,293 $4.81 Million
Q1 2022

May 13, 2022

SELL
$8.64 - $11.71 $104,803 - $142,042
-12,130 Reduced 1.29%
928,677 $8.02 Million
Q4 2021

Feb 14, 2022

BUY
$10.95 - $16.07 $611,283 - $897,107
55,825 Added 6.31%
940,807 $10.5 Million
Q3 2021

Nov 12, 2021

BUY
$12.95 - $18.24 $434,679 - $612,243
33,566 Added 3.94%
884,982 $11.5 Million
Q2 2021

Aug 13, 2021

BUY
$15.83 - $17.84 $13.5 Million - $15.2 Million
851,416 New
851,416 $14.1 Million

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $202M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.